Argos Therapeutics, Inc.' Phase 3 ADAPT Study for AGS-003 Highlighted During 11th Annual International Kidney Cancer Symposium
10/8/2012 9:37:48 AM
DURHAM, N.C., Oct. 8, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that the ADAPT study was highlighted in a presentation delivered by Robert Figlin, MD, FACP, during the 11th International Kidney Cancer Symposium in Chicago, Ill. The presentation focused on experimental immunotherapy and vaccine strategies during which Dr. Figlin reviewed the ongoing Phase 3 ADAPT study and progress to date.
comments powered by